Clinical trials
Liver Carcinoma clinical trials
Below are recruiting liver carcinoma clinical trials, each written for real people, not researchers. We’re tracking 177 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07101237Recruiting
Precision diagnosis and treatment study for liver cancer
This study aims to improve how doctors diagnose and treat liver cancer by combining advanced imaging tests and genetic analysis. It may help in choosing the most effective treatment for each person.
BeijingAges 18–70 - NCT07226869Recruiting
Computer-guided microwave ablation for liver cancer
This study tests a computer-guided microwave ablation procedure to destroy liver tumors. If you have early-stage liver cancer with up to 5 tumors, and one is 2-5 cm in size, you may be a candidate.
Boston, MassachusettsAges 18–90 - NCT06725121RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced liver cancer before transplant
This trial tests combining radiation therapy with immunotherapy (AtezoBev) before a liver transplant for advanced liver cancer. The goal is to see if this approach can shrink tumors and make transplant possible for more people.
London, OntarioAges 18–70 - NCT06179602Recruiting
Study of thermal ablation for liver tumors
This study follows patients who are having a procedure called thermal ablation to treat liver tumors. It aims to learn more about how well the procedure works and how safe it is.
LeidenAges 18–110 - NCT06265272Recruiting
PSMA-11 PET/MRI for Liver Cirrhosis
This study uses a special PET/MRI scan with a tracer called PSMA-11 to look at how liver cirrhosis affects the liver. It may help doctors better understand and monitor the disease.
Charlestown, MassachusettsAges 18–99 - NCT05199259Recruiting
Blood test study for people at risk for or with liver cancer
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
Escondido, CaliforniaAges 18 years+ - NCT07077356RecruitingPhase 1
mRNA vaccine for liver cancer patients awaiting transplant
This trial tests an mRNA vaccine for people with liver cancer who are waiting for a liver transplant. The vaccine is given to help control the cancer while they wait.
ChengduAges 18 years+ - NCT05992220RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
SeoulAges 20–79 - NCT07174570RecruitingPhase 2
Celecoxib with immunotherapy for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
Atlanta, GeorgiaAges 18 years+ - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT05276037Recruiting
PET/CT scan to guide liver transplant decisions in liver cancer
This trial studies how a whole-body PET/CT scan using a “tracer” called 18F-FDG can help decide which people with liver cancer (HCC) may benefit from a liver transplant. It may help the transplant team better sort out who is likely to do well after transplant.
AntwerpAges 18–80 - NCT06717295Recruiting
Blood test to find cancer early and track treatment
This study uses a blood test that looks at your platelets and immune cells to find common cancers early, and for certain cancers, to monitor how well treatment is working.
RosarioAges 40–75 - NCT06777628Recruiting
Blood test study to predict immunotherapy success in liver cancer
This study looks at blood cells from people with liver cancer (HCC) to see if we can predict early whether immunotherapy will work for them. It's a research study that involves blood tests during your normal care.
Bologna, Laura GramantieriAges 18 years+ - NCT07053072RecruitingPhase 1
PD-1 mRNA vaccine for advanced liver cancer
This trial tests a new mRNA vaccine for people with advanced liver cancer that has returned or spread after other treatments. The vaccine aims to help your immune system fight the cancer more effectively.
Chengdu, SichuanAges 18–70 - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT05304234RecruitingPhase 2
Testing ways to detect liver cancer risk in Native patients
This Phase 2 study focuses on people at higher risk for liver cancer due to liver scarring or chronic hepatitis B. It may help improve screening and outcomes for American Indian and Alaska Native people who could benefit from closer monitoring.
Tahlequah, OklahomaAges 18–75 - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT06658782Recruiting
MRI vs ultrasound for liver cancer detection in high-risk people
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Oxford, OxonAges 18 years+ - NCT07059936Recruiting
AI and scans to predict immunotherapy response in liver cancer
This study uses artificial intelligence (AI) to analyze your CT or MRI scans and help predict how well immunotherapy might work for your liver cancer. The goal is to find better ways to match you with the right treatment and improve your outcomes.
Wuhan, HubeiAges 18 years+ - NCT04933435Recruiting
Image-guided radiation plus liver procedures for non-surgical liver cancer
This trial studies a combination approach—special, image-guided radiation and liver procedures—for liver cancer patients who cannot have surgery. It may help shrink tumors while protecting liver function by using planned, targeted treatment.
Durham, North CarolinaAges 18 years+ - NCT06545630RecruitingPhase 1
Personalized immune cell vaccine for colorectal cancer with liver spread
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize colorectal cancer. It is for people who had surgery for colorectal cancer that spread to the liver and are now at high risk for the cancer returning.
Chengdu, Chengdu/SichuanAges 18–75 - NCT04539717Enrolling by invitation
Fast MRI test for liver cancer screening
This study tests a quicker MRI screening approach for people with cirrhosis to look for liver cancer early. It may help make liver cancer checkups faster and easier while still finding cancers when they are small.
Los Angeles, CaliforniaAges 18 years+ - NCT05863195RecruitingPhase 3
Pump chemotherapy plus standard chemo for liver-only colorectal spread
This study tests adding a chemotherapy “pump” directly into the liver along with standard chemotherapy, compared with standard chemotherapy alone. It’s for adults with colorectal cancer that has spread to the liver but cannot be surgically removed, and who are responding to first chemotherapy.
Birmingham, AlabamaAges 18 years+
Hear when a new Liver Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver carcinoma?
- Yes. Clin2 currently lists 177 recruiting liver carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.